STOCK TITAN

Vericel Corporation - VCEL STOCK NEWS

Welcome to our dedicated page for Vericel Corporation news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel Corporation stock.

Vericel Corporation (NASDAQ:VCEL) is a leading biopharmaceutical company dedicated to developing advanced, patient-specific cellular therapies for severe diseases and conditions. Founded in 1989 as Aastrom Biosciences, Vericel focuses on therapies for sports medicine and severe burn care. The company currently markets three key products in the United States: MACI®, Epicel®, and NexoBrid®.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product used to repair symptomatic, full-thickness cartilage defects in the knee. Epicel® (cultured epidermal autografts) serves as a permanent skin replacement for patients with deep dermal or full-thickness burns covering 30% or more of the total body surface area. Vericel also holds exclusive North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes that removes eschar in adults with deep partial- and full-thickness burns.

Vericel has shown strong financial performance with consistent revenue growth across its product lines. In the second quarter of 2023, Vericel reported a 24% increase in total net revenue to $45.9 million. Gross profit for the same period was $29.9 million, representing 65% of net revenue.

The company is poised for continued success with its plans to launch arthroscopic MACI, expected to further increase revenue growth in 2024. Additionally, the U.S. commercial availability of NexoBrid signifies a major expansion of Vericel's burn care franchise, offering a novel treatment for severe thermal burns by selectively targeting eschar while preserving viable tissue.

Vericel's mission is to help patients with severe conditions through innovative therapies. The company's commitment to growth and development is evident in its financial health, partnerships, and strategic initiatives aimed at expanding its market presence and enhancing its product portfolio.

Rhea-AI Summary
Vericel Corporation (VCEL) to present at 42nd Annual J.P. Morgan Healthcare Conference. Webcast available on Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reports record third quarter revenue of $45.6 million, an 18% growth versus the prior year. MACI revenue grew by 21% to $37.6 million. Full-year 2023 revenue guidance raised to $192.5-197.5 million. Positive results from NexoBrid Phase 3 DETECT study published in the Journal of Burn Care & Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will have its President and CEO and CFO present at the Stephens Annual Investment Conference on November 15, 2023. The webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2023 financial results on November 8, 2023. The company's management will host a conference call and webcast to discuss the results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences earnings
-
Rhea-AI Summary
Vericel Corporation announces positive results from Phase 3 DETECT study on NexoBrid treatment for severe burns, with over 90% of patients achieving complete eschar removal and reduced need for surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
-
Rhea-AI Summary
Vericel launches NexoBrid for eschar removal in burn patients, expanding market potential. NexoBrid offers faster and more precise removal of eschar, reducing need for skin grafting. Represents a paradigm shift in burn treatment. Market potential estimated at $300 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
Rhea-AI Summary
Vericel Corporation's CEO to participate in fireside chat at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reported a record second quarter total revenue of $45.9 million, with 24% growth versus the prior year. MACI revenue grew by 27% to $36.3 million, and Epicel revenue grew by 17% to $9.6 million. The full-year 2023 revenue guidance has been raised to $190-197 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
conferences earnings
Rhea-AI Summary
Vericel Corporation reported record first-quarter total revenue of $41 million, with MACI revenue increasing by 32% to $34.2 million. Full-year 2023 revenue guidance has been raised to $184-$192 million. The company also highlighted positive business highlights, including the highest number of surgeons using MACI biopsies and progress on the NexoBrid program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags

FAQ

What is the current stock price of Vericel Corporation (VCEL)?

The current stock price of Vericel Corporation (VCEL) is $57.42 as of January 23, 2025.

What is the market cap of Vericel Corporation (VCEL)?

The market cap of Vericel Corporation (VCEL) is approximately 2.9B.

What products does Vericel Corporation market?

Vericel markets MACI® for cartilage defects in the knee, Epicel® for severe burn treatment, and NexoBrid® for eschar removal.

What is MACI® used for?

MACI® is used for the repair of symptomatic, full-thickness cartilage defects in the knee.

What is Epicel®?

Epicel® is a permanent skin replacement for patients with deep dermal or full-thickness burns covering 30% or more of the total body surface area.

What is NexoBrid®?

NexoBrid® is a biological orphan product containing proteolytic enzymes used for eschar removal in adults with deep partial- and full-thickness burns.

How did Vericel perform financially in the second quarter of 2023?

In Q2 2023, Vericel reported a 24% increase in total net revenue to $45.9 million and a gross profit of $29.9 million, representing 65% of net revenue.

What are Vericel's financial prospects for 2024?

Vericel expects strong revenue growth in 2024 driven by the launch of arthroscopic MACI and contributions from NexoBrid.

When was Vericel Corporation founded?

Vericel Corporation was founded in 1989 as Aastrom Biosciences.

What is the significance of NexoBrid®'s commercial availability in the U.S.?

The commercial availability of NexoBrid® in the U.S. expands Vericel's burn care franchise and offers a new treatment for severe burns by selectively targeting eschar while preserving viable tissue.

What is Vericel's mission?

Vericel's mission is to develop advanced, patient-specific cellular therapies to help patients with severe diseases and conditions.

What is the significance of Vericel's recent financial performance?

Vericel's recent financial performance, including consistent revenue growth and robust gross profits, indicates strong business fundamentals and financial health.
Vericel Corporation

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.92B
48.90M
0.92%
104.51%
7.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE